Percentage of T25FW responders over shorter-term (6–8 months) and longer-term (24–30 months) follow-up in disabled RRMSa and SPMS subjects during treatment with natalizumab compared with placebo or IM IFNβ-1a.
收藏Figshare2015-12-02 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Percentage_of_T25FW_responders_over_shorter_term_6_8_months_and_longer_term_24_30_months_follow_up_in_disabled_RRMS_a_and_SPMS_subjects_during_treatment_with_natalizumab_compared_with_placebo_or_IM_IFN_1a_/183522
下载链接
链接失效反馈官方服务：
资源简介：
aDisabled RRMS subjects defined as those with EDSS ≥3.5 and T25FW >5 seconds at baseline.bIn SENTINEL, subjects on IM IFNβ-1a for at least 12 months were randomized to adding natalizumab or placebo.T25FW, timed 25-foot walk; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; IM, intramuscular; IFNβ-1a, interferon beta-1a; EDSS, Expanded Disability Status Scale.
创建时间：
2015-12-02
